Roche Holding AG (OTCMKTS:RHHBY) Shares Sold by Puzo Michael J

Puzo Michael J decreased its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 1.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,950 shares of the company’s stock after selling 275 shares during the quarter. Puzo Michael J’s holdings in Roche were worth $986,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of RHHBY. GAMMA Investing LLC boosted its stake in Roche by 6,463.8% during the first quarter. GAMMA Investing LLC now owns 528,778 shares of the company’s stock worth $21,759,000 after buying an additional 520,722 shares during the last quarter. Boston Common Asset Management LLC raised its holdings in shares of Roche by 10.0% during the 1st quarter. Boston Common Asset Management LLC now owns 325,732 shares of the company’s stock worth $13,369,000 after acquiring an additional 29,522 shares during the period. Altrius Capital Management Inc boosted its position in shares of Roche by 0.3% during the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company’s stock valued at $6,399,000 after acquiring an additional 603 shares during the last quarter. Bard Financial Services Inc. grew its holdings in shares of Roche by 25.3% in the first quarter. Bard Financial Services Inc. now owns 138,900 shares of the company’s stock valued at $5,716,000 after purchasing an additional 28,050 shares during the period. Finally, Rhumbline Advisers increased its position in Roche by 7.4% during the first quarter. Rhumbline Advisers now owns 107,252 shares of the company’s stock worth $4,413,000 after purchasing an additional 7,374 shares during the last quarter.

Roche Price Performance

Shares of RHHBY opened at $40.02 on Wednesday. The firm’s fifty day simple moving average is $39.63 and its 200-day simple moving average is $39.11. Roche Holding AG has a twelve month low of $33.76 and a twelve month high of $44.31. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.20 and a current ratio of 1.48.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RHHBY. Hsbc Global Res lowered Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.